Cellular Biomedicine Group to Present Osteoarthritis Stem Cell Rejoin(TM) Therapy and Cancer CAR-T Therapy Clinical Developme...
March 18 2015 - 9:22AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases,
announced today that Dr. William (Wei) Cao, Chief Executive Officer
of the Company will discuss the Company's Phase IIb interim
clinical data on its Rejoin TM human adipose-derived mesenchymal
progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) and
its CAR-T cell therapy for cancer clinical development programs at
the 2015 Annual Regen Med Investor Day to be held on Wednesday,
March 25, 2015 at 11:20 AM EDT at the Metropolitan Club in New York
City.
A live-streaming webcast of all panels and company presentations
will be available at: http://www.arminvestorday.com/webcast. The
Company's presentation will be published on the event's website
shortly after the conference and will be posted on the Company's
website at http://cellbiomedgroup.com/newsroom/.
Organized by the Alliance for Regenerative Medicine (ARM) and
co-hosted with Piper Jaffray, this one-day investor meeting
provides institutional, strategic and venture investors with unique
insight into the financing hypothesis for advanced therapies-based
treatment and tools. The program includes clinical and commercial
experts who are on-hand to address specific questions regarding the
outlook for these products, as well as offer insight into how
advanced therapies could impact the standard of care in key
therapeutic areas. In addition to presentations by more than 30
leading companies from across the globe, the event includes
dynamic, interactive panels featuring research analysts covering
the space, key clinical opinion leaders and top company CEOs. These
discussions will explore themes specific to cell and gene therapy
such as commercialization, market access and pricing for
breakthrough technologies, gene therapy delivery and upcoming
milestones in the adoptive T-cell therapy space.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347-481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024